Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Liver Diseases

Free Subscription 03.11.2025 1 Anticancer Res 2 Biochem Biophys Res Commun 6 BMC Cancer 3 BMC Gastroenterol 4 Dig Dis Sci 5 Eur Radiol 1 Gut 3 Hepatology 2 J Gastroenterol 3 J Hepatol 9 PLoS One 2 Pol J Radiol 1 Radiol Imaging Cancer 1 Radiology 1 Semin Liver Dis

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Anticancer Res

1. XUE X, Huang Q, Bai X, Yang J, et al
   Combination Strategy of Arsenic Trioxide and its Metabolite For Leukemia Treatment and Modulation of Endoplasmic Reticulum-mediated Hepatotoxicity.
   Anticancer Res. 2025;45:4941-4958.
   PubMed         Abstract available
   
   

   
   Biochem Biophys Res Commun

2. KAWAKITA I, Honda S, Yamada Y, Tanaka S, et al
   PAGE4, upregulated in a novel iPSC-derived hepatoblastoma model, promotes hepatoblastoma progression.
   Biochem Biophys Res Commun. 2025;790:152824.
   PubMed         Abstract available
   
   
3. HIDALGO I, Ortiz-Flores M, Perez-Duran J, Ceballos G, et al
   Modulation of molecular and serological biomarkers by (-)-epicatechin consumption on a murine model of metabolic dysfunction-associated steatotic liver disease.
   Biochem Biophys Res Commun. 2025;786:152759.
   PubMed         Abstract available
   
   

   
   BMC Cancer

4. MA Y, Chen M, Xu Z
   Clinicopathological significance of AKT and phosphorylated AKT expression in hepatocellular carcinoma: A Meta-Analysis.
   BMC Cancer. 2025;25:1677.
   PubMed         Abstract available
   
   
5. ZHANG X, Fang X, Wang R, Xiong B, et al
   Efficacy and safety of DEB-TACE combined with HAIC and donafenib in the treatment of unresectable hepatocellular carcinoma: a dual-center retrospective study.
   BMC Cancer. 2025;25:1683.
   PubMed         Abstract available
   
   
6. LIU D, Yang Z, Wang L, Ma L, et al
   Comparative efficacy and safety of immune checkpoint inhibitors combined with antiangiogenic agents for unresectable hepatocellular carcinoma in patients with Child-Pugh A versus B cirrhosis: a single-center, retrospective study.
   BMC Cancer. 2025;25:1651.
   PubMed         Abstract available
   
   
7. LEE PC, Li PY, Lee CY, Lin SR, et al
   Characterizing immune profiles in hepatocellular carcinoma patients benefiting from pembrolizumab and lenvatinib using machine learning.
   BMC Cancer. 2025;25:1641.
   PubMed         Abstract available
   
   
8. ZHANG Y, Lin Y, Cai H, Zhou T, et al
   EZH2 confers lenvatinib resistance in hepatocellular carcinoma by suppressing ACSL1-Mediated ferroptosis.
   BMC Cancer. 2025;25:1638.
   PubMed         Abstract available
   
   
9. LI Z, Fu Y, Wei Y, Zhu Y, et al
   Integrated multi-omics analysis reveals NOL11 as a novel prognostic biomarker for hepatocellular carcinoma.
   BMC Cancer. 2025;25:1635.
   PubMed         Abstract available
   
   

   
   BMC Gastroenterol

10. RAHAOUI M, Fakhrddine A, Elmqaddem O, Koulali H, et al
    Elevated serum ferritin as a predictor of complications in cirrhotic patients: a retrospective cohort study.
    BMC Gastroenterol. 2025;25:761.
    PubMed         Abstract available
    
    
11. MA S, Yang M, Qiang W, Zhou F, et al
    Regulatory effects of miR-30c knockout on hepatic lipid metabolism and progression of liver fibrosis.
    BMC Gastroenterol. 2025;25:777.
    PubMed        
    
    
12. SHAO L, Zhang B, Liu J, Lyu Z, et al
    Early elevation of complement-related proteins in metabolic dysfunction-associated steatotic liver disease (MASLD) with normal liver enzymes.
    BMC Gastroenterol. 2025;25:772.
    PubMed         Abstract available
    
    

    
    Dig Dis Sci

13. SILVA ML, Prado R
    Systematic Mapping of Worldwide Research on Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-Associated Steatohepatitis (MASH).
    Dig Dis Sci. 2025 Oct 25. doi: 10.1007/s10620-025-09498.
    PubMed         Abstract available
    
    
14. BHARADWAJ HR, Dahiya DS, Dalal P, Fuad M, et al
    Artificial Intelligence in Population-Level Gastroenterology and Hepatology: A Comprehensive Review of Public Health Applications and Quantitative Impact.
    Dig Dis Sci. 2025 Oct 24. doi: 10.1007/s10620-025-09452.
    PubMed         Abstract available
    
    
15. LEE SS, Thornton LM, Jones PD, Goldberg DS, et al
    Investigating Disparities Related to Insurance Status and Access to Locoregional Therapies for Patients with Hepatocellular Carcinoma Awaiting Liver Transplantation.
    Dig Dis Sci. 2025 Nov 1. doi: 10.1007/s10620-025-09462.
    PubMed         Abstract available
    
    
16. BISWAS S, Mehta S, Swaroop S, Aggarwal A, et al
    Clinical Outcomes of Intravenous Albumin Administration After Acute Variceal Hemorrhage in Patients with Cirrhosis: An Open-Label, Randomized Controlled Trial.
    Dig Dis Sci. 2025 Oct 27. doi: 10.1007/s10620-025-09485.
    PubMed         Abstract available
    
    

    
    Eur Radiol

17. OCAL O, Zech CJ, Bali MA, Pasquier D, et al
    Correction: Imaging in staging, treatment planning, and monitoring of hepatocellular carcinoma for local and locoregional therapies: consensus recommendations from EORTC and ESGAR.
    Eur Radiol. 2025 Oct 31. doi: 10.1007/s00330-025-12045.
    PubMed        
    
    
18. SHI D, Kou Q, Chen HY, Chen JY, et al
    Quantitative analysis of enhanced CT in predicting microvascular invasion and pathological grading of hepatocellular carcinoma.
    Eur Radiol. 2025 Oct 31. doi: 10.1007/s00330-025-12087.
    PubMed         Abstract available
    
    
19. JIA X, Jiang H, Ye Z, Wei H, et al
    Imaging for molecular and pathological subtyping of hepatocellular carcinoma-a critical appraisal and future directions.
    Eur Radiol. 2025 Oct 30. doi: 10.1007/s00330-025-12075.
    PubMed         Abstract available
    
    
20. KIM YY, Chang W, Lee JM, Kim SW, et al
    Hepatocellular carcinoma risk stratification to identify patients suitable for intensive surveillance in viral hepatitis: the SELECT score.
    Eur Radiol. 2025 Oct 25. doi: 10.1007/s00330-025-12060.
    PubMed         Abstract available
    
    
21. YOSHIZAWA E, Yamada A, Okajima Y, Notake T, et al
    Harmonization of quantitative liver function evaluation using gadoxetate disodium-enhanced magnetic resonance imaging.
    Eur Radiol. 2025;35:7372-7381.
    PubMed         Abstract available
    
    

    
    Gut

22. ZHANG M, Chen C, Zhang H, Long T, et al
    SIRT6 promotes intrahepatic cholangiocarcinoma development by reprogramming glutamine metabolism via enhanced GLUL.
    Gut. 2025 Oct 23:gutjnl-2025-335729. doi: 10.1136/gutjnl-2025-335729.
    PubMed         Abstract available
    
    

    
    Hepatology

23. WEI T, Ma ZJ, Guo S, Weiss M, et al
    Satellite lesions versus intrahepatic metastasis in multifocal intrahepatic cholangiocarcinoma: Prognostic impact and genomic profiling.
    Hepatology. 2025 Oct 30. doi: 10.1097/HEP.0000000000001594.
    PubMed         Abstract available
    
    
24. HAN J, Zhao Y, Zhao J
    Yttrium-90 superiority in hepatocellular carcinoma downstaging: Treatment effect or selection bias?
    Hepatology. 2025 Oct 28. doi: 10.1097/HEP.0000000000001579.
    PubMed        
    
    
25. ANTON A, Shalaby S, Botero ML, Blasi A, et al
    Endothelial-to-mesenchymal transition: A targetable mechanism that contributes to portal vein thrombosis in cirrhosis.
    Hepatology. 2025 Oct 6. doi: 10.1097/HEP.0000000000001547.
    PubMed         Abstract available
    
    

    
    J Gastroenterol

26. TAHATA Y, Hikita H, Takaki A, Kurosaki M, et al
    Long-term changes in hepatic reserve and prognosis after direct-acting antiviral treatment in patients with hepatitis C virus-related decompensated cirrhosis: a five-year follow-up study of a Japanese phase 3 trial.
    J Gastroenterol. 2025 Oct 30. doi: 10.1007/s00535-025-02312.
    PubMed         Abstract available
    
    
27. MAESAKA K, Hikita H, Tahata Y, Nishioka C, et al
    Comparative analysis of lenvatinib use after atezolizumab plus bevacizumab versus lenvatinib as first-line therapy in unresectable hepatocellular carcinoma.
    J Gastroenterol. 2025 Oct 25. doi: 10.1007/s00535-025-02308.
    PubMed         Abstract available
    
    

    
    J Hepatol

28. BANARES J, Pons M, Reiberger T, Mandorfer M, et al
    Refining the Baveno VII criteria for clinically significant portal hypertension: an individual-patient data meta-analysis.
    J Hepatol. 2025 Oct 23:S0168-8278(25)02565-6. doi: 10.1016/j.jhep.2025.
    PubMed         Abstract available
    
    
29. LAMARQUE C, Segaux L, Bachellier P, Buchard B, et al
    Corrigendum to: "Evaluation of a delayed liver transplantation strategy for patients with HCC receiving bridging therapy: the DELTA-HCC study" [J Hepatol (2024) 278-288].
    J Hepatol. 2025 Oct 27:S0168-8278(25)02553-X. doi: 10.1016/j.jhep.2025.
    PubMed        
    
    
30. CUI T, Sun L, Guo X, Cheng C, et al
    Corrigendum to 'Tumor-derived CD109 orchestrates reprogramming of tumor-associated macrophages to dampen immune response' (J Hepatol 2025 [946-958]).
    J Hepatol. 2025 Oct 27:S0168-8278(25)02554-1. doi: 10.1016/j.jhep.2025.
    PubMed        
    
    

    
    PLoS One

31. GYOUTOKU N, Inoguchi Y, Rikitake J, Demiya M, et al
    Effect of imeglimin on metabolic dysfunction-associated steatotic liver disease in individuals with type 2 diabetes.
    PLoS One. 2025;20:e0335888.
    PubMed         Abstract available
    
    
32. ZHANG P, Yang S, Hu R, Peng T, et al
    Comparative mortality outcomes in metabolic dysfunction-associated steatotic liver disease and nonalcoholic fatty liver disease subtypes in the United States.
    PLoS One. 2025;20:e0335230.
    PubMed         Abstract available
    
    
33. LI Y, Liu Z, Qian Y, Wang K, et al
    Ultrasounic-radiomics models for predicting the response to Atezolizumab plus Bevacizumab in patients with unresectable hepatocellular carcinoma.
    PLoS One. 2025;20:e0334099.
    PubMed         Abstract available
    
    
34. NORLIN J, Dermit M, Sidiropoulos N, Galsgaard ED, et al
    The combination of zalfermin and semaglutide has additive therapeutic effects in a diet-induced obese and biopsy-confirmed mouse model of MASH.
    PLoS One. 2025;20:e0331665.
    PubMed         Abstract available
    
    
35. FREY LJ, Fuchs M, Ward RC, Gebregziabher M, et al
    Use of machine learning for early prediction of short-term mortality in veterans with metabolic dysfunction-associated steatotic liver disease.
    PLoS One. 2025;20:e0334715.
    PubMed         Abstract available
    
    
36. ALOWAIESH BF, Ibrahim D, Saleh AA, Alhaithloul HAS, et al
    Exosomes combined with extra virgin olive oil reduces lipogenesis, oxidative stress, and inflammation in non-alcoholic fatty liver disease model.
    PLoS One. 2025;20:e0333698.
    PubMed         Abstract available
    
    
37. PETER-MARSKE KM, Zhang X, Wang T, Liu X, et al
    Prevalence and characteristics of metabolic dysfunction-associated steatohepatitis among pediatric patients in the MarketScan Databases.
    PLoS One. 2025;20:e0334971.
    PubMed         Abstract available
    
    
38. KHODAEI M, Torki M, Khajali F, Karimi I, et al
    Application of various mixtures of medicinal herbs in the diet of laying hens: Evaluating preventive approach of fatty liver syndrome.
    PLoS One. 2025;20:e0330363.
    PubMed         Abstract available
    
    
39. PHUONG LINH TQ, Nhan NT, Thuan LM, Phuong LT, et al
    Survey of clot waveform analysis of normal activated partial thromboplastin time in patients with cirrhosis and sepsis at Le Van Thinh hospital.
    PLoS One. 2025;20:e0334920.
    PubMed         Abstract available
    
    

    
    Pol J Radiol

40. PYRA K, Mikos E, Szmygin M, Swiatlowski L, et al
    Transarterial chemoembolization with bleomycin and lipiodol: a novel treatment for giant hepatic haemangiomas.
    Pol J Radiol. 2025;90:e465-e470.
    PubMed         Abstract available
    
    
41. POLEWIAK P, Cebula M, Kufel J, Olchowy C, et al
    Is hepatosteatosis overlooked in ultrasound relying only on B-mode? The impact of incorporating the attenuation coefficient into the standard abdominal ultrasound protocol.
    Pol J Radiol. 2025;90:e431-e437.
    PubMed         Abstract available
    
    

    
    Radiol Imaging Cancer

42. ZHANG Y, Wang S, Song M, Sheng R, et al
    MRI-based Intra- and Peritumoral Heterogeneity in Hepatocellular Carcinoma for Microvascular Invasion Prediction and Prognostic Risk Stratification.
    Radiol Imaging Cancer. 2025;7:e250066.
    PubMed         Abstract available
    
    

    
    Radiology

43. FOWLKES JB
    Microbubbles, Ultrasound, and Radiation: Finding the Treatment Synergy for Hepatocellular Carcinoma.
    Radiology. 2025;317:e252815.
    PubMed        
    
    

    
    Semin Liver Dis

44. XU S, Calderaro J
    Combined hepatocellular-cholangiocarcinoma: a clinical and molecular review.
    Semin Liver Dis. 2025 Oct 24. doi: 10.1055/a-2730-9074.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Liver Diseases is free of charge.